The negative impact of biological variation in the effect and clearance of warfarin on methods for prediction of dose requirements
- PMID: 3563968
The negative impact of biological variation in the effect and clearance of warfarin on methods for prediction of dose requirements
Abstract
Within-individual variation over time in the clearance (Cl) and effect (PT%) of warfarin, was measured in 25 inpatients (group I) studied after standard single or individualized split loading doses and 1-3 times (n = 16) 8-16 weeks later during maintenance. Mean Cl (2.5 +/- 0.9 ml/min) was similar in both phases but significant changes occurred in 6/16 patients, exceeding those expected from within-individual variation alone (defined by its 95% tolerance limits -24% to +62%). Initial PT% (21 +/- 5) was unaffected by dosing schedule, total or free plasma warfarin, varying between patients by only 18-24%. Mean initial and maintenance dose-PT% ratios (8.2 mg/d: 21% and 4.1 mg/d: 40%) were similar but significant changes in sensitivity to warfarin occurred in 4/16 patients. In group I and 64 other outpatients on maintenance therapy, between-individual variability was 36-52% for Cl and 49-56% for effect. PT% correlated best (r = 0.56) with free and total plasma warfarin but poorly with dose (r = 0.29), with only 30% of PT% variance explained at best, due to high between patient variability. Warfarin dose prediction whether based on extrapolation from initial effects to the maintenance phase, or on iterative methods not allowing for between- or within-patient variation in warfarin clearance or effect which may occur independently over time, have not improved on empirical therapy. This, due to the elements of biological variability as well as the intricacy of the warfarin-prothrombin complex interaction not captured by any kinetic-dynamic model used for prediction to date.
Similar articles
-
Multicenter evaluation of six methods for predicting warfarin maintenance-dose requirements from initial response.Clin Pharm. 1985 Jul-Aug;4(4):440-6. Clin Pharm. 1985. PMID: 3899472 Clinical Trial.
-
Evaluation of three dosage-prediction methods for initial in-hospital stabilization of warfarin therapy.Clin Pharm. 1987 Jan;6(1):37-45. Clin Pharm. 1987. PMID: 3816105 Clinical Trial.
-
Effect of using warfarin plasma concentrations in Bayesian forecasting of prothrombin-time response.Clin Pharm. 1987 May;6(5):406-12. Clin Pharm. 1987. PMID: 3665392
-
Racial and ethnic differences in warfarin response.J Heart Valve Dis. 2004 Jan;13(1):15-21. J Heart Valve Dis. 2004. PMID: 14765833 Review.
-
Initiating warfarin therapy: 5 mg versus 10 mg.Ann Pharmacother. 2004 Dec;38(12):2115-21. doi: 10.1345/aph.1E083. Epub 2004 Nov 2. Ann Pharmacother. 2004. PMID: 15522981 Review.
Cited by
-
Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy.Br J Clin Pharmacol. 1999 Jul;48(1):63-70. doi: 10.1046/j.1365-2125.1999.00967.x. Br J Clin Pharmacol. 1999. PMID: 10383562 Free PMC article.
-
Rapid melting curve analysis for genetic variants that underlie inter-individual variability in stable warfarin dosing.J Thromb Thrombolysis. 2008 Aug;26(1):1-7. doi: 10.1007/s11239-007-0077-x. Epub 2007 Jul 29. J Thromb Thrombolysis. 2008. PMID: 17661181
-
An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction.J Thromb Thrombolysis. 2010 Oct;30(3):358-64. doi: 10.1007/s11239-010-0467-3. J Thromb Thrombolysis. 2010. PMID: 20499136
-
Warfarin maintenance dose Prediction for Patients undergoing heart valve replacement- a hybrid model with genetic algorithm and Back-Propagation neural network.Sci Rep. 2018 Jun 26;8(1):9712. doi: 10.1038/s41598-018-27772-9. Sci Rep. 2018. PMID: 29946101 Free PMC article.
-
Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.J Thromb Thrombolysis. 2006 Dec;22(3):191-7. doi: 10.1007/s11239-006-9030-7. J Thromb Thrombolysis. 2006. PMID: 17111199
MeSH terms
Substances
LinkOut - more resources
Medical